Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an indian population with type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 11, Issue 8, 2009, Pages 517-521

  Kesavadev, Jothydev ^a   Balakrishnan, Shyam ^a   Ahammed, Shebeer ^a   Jothydev, Sunitha ^a  

^a Jothydev's Diabetes and Research Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DAILY LIFE ACTIVITY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG DOSE REGIMEN; DYSLIPIDEMIA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN INFUSION; INSULIN PUMP; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION;

BODY WEIGHT; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIA; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PATIENT SELECTION;

EID: 70349459325     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0128     Document Type: Article

References (17)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431.
2. Pearson J, Bergenstal R. Fine-tuning control: Pattern management versus supplementation. View 1: Pattern management: An essential component of effective insulin management. Diabetes Spectrum 2001;14:75-78.
3. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28: 1568-1573.
4. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603.
5. Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I: Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet Med 2005;22:1037-1046.
6. Peyrot M, Rubin RR: Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: The Insulin Delivery System Rating Questionnaire. Diabetes Care 2005;28:53-58.
7. Bloomgarden ZT: Approaches to treatment of type 2 diabetes. Diabetes Care 2008;31:1697-1703.
8. Hammond P: NICE guidance on insulin pump therapy: Time for a re-appraisal? Pract Diabet Int 2005;22:115-116.
9. Pickup JC, Kidd J, Burmiston S, Yemane N: Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: Importance of blood glucose variability. Diabetes Metab Res Rev 2006;22:232-237.
10. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B: Continuous subcutaneous insulin infusion versus multiple daily injections: The impact of baseline A1c. Diabetes Care 2004;27:2590-2596.
11. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554-1558.
12. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28:533-538.
13. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758.
14. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F: Use of insulin pump therapy in the pediatric age-group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007;30:1653-1662.
15. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ: Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005; 22:1239-1245.
16. Scuffham P, Carr L: The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586-593.
17. Kesavadev J, Rasheed SA: Dramatic response of painful peripheral neuropathy with insulin pump in type 2 diabetes [ADA 2007 abstract 2097-PO]. http://professional.diabetes.org/Abstracts-Display.aspx?TYP&1&CID=55571 (accessed May 20, 2009).